Archives
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Once apoptosis has been initiated
2024-01-26

Once apoptosis has been initiated the HMGA proteins themselves undergo marked changes in both the types and extent of their post-translational modifications (PTMs; review in [149,175]), some of which are likely correlated with alterations in chromatin structure. For example, the early stages of apop
-
APP is a member of a conserved protein
2024-01-26

APP is a member of a conserved protein family that also includes amyloid precursor-like proteins 1 and 2 (APLP1, APLP2).8, 9, 10 The proteins in this family are type I single-pass transmembrane tropisetron with receptor-like structural features but not entirely clear cellular functions.11, 12, 13, 1
-
Our research group has been involved by many years
2024-01-26

Our research group has been involved by many years in the synthesis of new 2,3-benzodiazepin-4-ones (e.g. 1, Fig. 1) and in the characterization of their mechanism of action.15, 16, 17 Within the development of these compounds, we demonstrated that an improvement of AMPAR antagonism by 2,3-benzodiaz
-
BITC significantly enhanced the gene expression of the Nrf d
2024-01-26

BITC significantly enhanced the gene expression of the Nrf2-dependent genes, such as NQO1 and HO-1 (Fig. 4), as well as the ALDH genes (Fig. 2). Nrf2 is a key transcriptional factor which activates the expression of the genes that contain ARE in their promoter. Nrf2 translocates to the nucleus where
-
MDV 3100 br Introduction Clinical manifestations of Alzheime
2024-01-26

Introduction Clinical manifestations of Alzheimer's disease (AD) are mainly characterized by progressive intellectual deterioration, memory impairment, cognitive impairment, and psychiatric symptoms. The pathogenesis of AD remains unclear, mainly containing genetic factors, neurotransmitter disor
-
There is also a literature on the impact of commodity
2024-01-26

There is also a literature on the impact of commodity (consumption) taxation under imperfect competition. Besley (1989) applies a Cournot model, in which production takes place under IRS and in which free entry leads to an excessive number of firms in the market. Introducing a distortive specific co
-
br Conclusions br Conflicts of interest
2024-01-26

Conclusions Conflicts of interest Acknowledgements This work was supported by Ege University Research Fund [BAP, 14-ECZ-030, 2016]. Introduction The interest in the effects of endocrine disrupting chemicals (EDCs) in the aquatic environment continues to increase over the past decade, sp
-
Many metalloenzyme inhibitors consist of two chemical compon
2024-01-26

Many metalloenzyme inhibitors consist of two chemical components: the MBG, the portion of the inhibitor designed to bind to the metal, and the scaffold, the portion of the inhibitor recognized by the amino Flubendazole mg residues that form the substrate-binding site of the metalloenzyme. The MGB i
-
Tenovin-3 An AXL decoy receptor with enhanced GAS binding pr
2024-01-26

An AXL decoy receptor with enhanced GAS6-binding properties, MYD1, was engineered as a therapeutic tool to disrupt GAS6/AXL signaling in vivo (Kariolis et al., 2014). MYD1 was shown to block metastasis of human ovarian cancer Tenovin-3 and a murine breast cancer cell line in grafting assays in mice
-
Screening a selection of analogues from this library
2024-01-25

Screening a selection of analogues from this library against the panel of 26 kinases (16, 22, and 24 were screened at 30 μM due to poor solubility; 17 tested at 100 μM) generally demonstrated an increase in activity compared to Metronidazole 3 (Fig. 3, Fig. 6). The benzamide analogue 16 demonstrated
-
The therapeutic potential of ML induced
2024-01-25

The therapeutic potential of ML327-induced MET against UO126 of mesenchymal origin has not been explored. In the present study, we hypothesized that induction of MET using ML327 would block the growth of ES cells and sensitize to TRAIL-mediated apoptosis. Herein, we report that ML327 induces apopto
-
Despite their different effects on cell survival
2024-01-25

Despite their different effects on cell survival, the functions of autophagy and apoptosis are not completely independent. Additionally, Cho et al. (2009) suggested that the mediation of caspase-3 links the apoptotic and autophagic signaling pathways. Consequently, to illuminate the correlation, exc
-
The protein kinase CK mediated phosphorylation of HMGN was
2024-01-25

The protein kinase CK2-mediated phosphorylation of HMGN1 was implicated to be involved in age-associated amnesia in rats [31]. It was shown that the decreased level of HMGN1 phosphorylation due to the down-regulation of CK2 activity could cause amnesia in aged rats, whereas the treatment with protei
-
br Introduction AMPA receptors AMPARs
2024-01-25

Introduction AMPA receptors (AMPARs) mediate the majority of fast excitatory postsynaptic currents (EPSCs) in the nebivolol hcl synthesis (Jonas, 2000). The brevity of EPSCs and rapid deactivation of AMPARs depend upon a short lifetime of synaptically released glutamate, estimated to be about 1
-
Both AD and dyslipidemias are global
2024-01-25

Both AD and dyslipidemias are global public health problems, and an increase in their incidence over the next decades is expected. Among many triggering elements, the increase in life expectancy is one of the main risk factors associated with the increase in the incidence of AD. Meanwhile, dyslipide
8601 records 240/574 page Previous Next First page 上5页 236237238239240 下5页 Last page